EOLS Evolus Inc

In a report released today, Serge Belanger from Needham maintained a Buy rating on Evolus (EOLS - Research Report), with a price target of $18.00. The company's shares closed yesterday at $7.78.According to TipRanks, Belanger is an analyst with an average return of -5.2% and a 37.50% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Revance Therapeutics, and KalVista Pharmaceuticals.Evolus has an analyst consensus of Strong Buy, with a price target consensus of $16.00, representing a 105.66% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
https://www.tipranks.com/news/blurbs/needham-keeps-their-buy-rating-on-evolus-eols?utm_source=advfn.com&utm_medium=referral